Increasing pharmacoequity for people with cirrhosis.

作者信息

Hundt Melanie A, Kardashian Ani A

机构信息

Department of Medicine, Los Angeles General Hospital, Los Angeles, California, USA.

Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.

出版信息

Clin Liver Dis (Hoboken). 2024 Jun 7;23(1):e0203. doi: 10.1097/CLD.0000000000000203. eCollection 2024 Jan-Jun.

DOI:10.1097/CLD.0000000000000203

PMID:38860125

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11164002/

Abstract

摘要

相似文献

[1]

Increasing pharmacoequity for people with cirrhosis.

Clin Liver Dis (Hoboken). 2024-6-7

[2]

Pharmacoequity and Biologics in the Allergy Clinic: Providing the Right Care, at the Right Time, Every Time, to Everyone.

J Allergy Clin Immunol Pract. 2024-5

[3]

Pursuing Pharmacoequity: Determinants, Drivers, and Pathways to Progress.

J Health Polit Policy Law. 2022-12-1

[4]

Eliminating Health Disparities in Atrial Fibrillation, Heart Failure, and Dyslipidemia: A Path Toward Achieving Pharmacoequity.

Curr Atheroscler Rep. 2023-12

[5]

Pharmacoequity in Allergy-Immunology: Disparities in Access to Medications for Allergic Diseases and Proposed Solutions in the United States and Globally.

J Allergy Clin Immunol Pract. 2024-2

[6]

Reducing Health Disparities Through Achieving Pharmacoequity.

JAMA. 2022-2-8

[7]

Reducing Health Disparities Through Achieving Pharmacoequity.

JAMA. 2022-2-8

[8]

Reducing Health Disparities Through Achieving Pharmacoequity-Reply.

JAMA. 2022-2-8

[9]

Pharmacoequity for Older Adults With Inflammatory Bowel Diseases.

Clin Gastroenterol Hepatol. 2024-2

[10]

Examining Pharmacoequity in Older Inflammatory Bowel Disease Patients.

Gastroenterol Hepatol (N Y). 2024-8

本文引用的文献

[1]

A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis.

N Engl J Med. 2024-2-8

[2]

Culture, stigma, and inequities creating barriers in alcohol use disorder management in alcohol-associated liver disease.

Clin Liver Dis (Hoboken). 2023-3-20

[3]

Medications for alcohol use disorder improve survival in patients with hazardous drinking and alcohol-associated cirrhosis.

Hepatol Commun. 2023-4-1

[4]

Racial, Ethnic, and Socioeconomic Inequities in Glucagon-Like Peptide-1 Receptor Agonist Use Among Patients With Diabetes in the US.

JAMA Health Forum. 2021-12

[5]

Vital Signs: Hepatitis C Treatment Among Insured Adults - United States, 2019-2020.

MMWR Morb Mortal Wkly Rep. 2022-8-12

[6]

Changing Epidemiology of Cirrhosis and Hepatic Encephalopathy.

Clin Gastroenterol Hepatol. 2022-8

[7]

Racial and ethnic disparities in early treatment with immunotherapy for advanced HCC in the United States.

Hepatology. 2022-12

[8]

Racial and ethnic disparities in rifaximin use and subspecialty referrals for patients with hepatic encephalopathy in the United States.

J Hepatol. 2022-8

[9]

Removal of medicaid restrictions were associated with increased hepatitis C virus treatment rates, but disparities persist.

J Viral Hepat. 2022-5

[10]

A Policy Prescription for Reducing Health Disparities-Achieving Pharmacoequity.

JAMA. 2021-11-9

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

新学期，新优惠

Increasing pharmacoequity for people with cirrhosis.

作者信息

机构信息

出版信息

相似文献

本文引用的文献

文献AI研究员

用中文搜PubMed

推荐工具

Suppr 超能文献

相似文献

本文引用的文献